Inflammatory dermatoses are the most common chronic skin diseases of multifactorial genesis, contributing to severe social maladjustment of patients and significant financial costs for patients and the state. Impaired functional activity of the epidermal barrier and changes in the expression of antimicrobial peptides form the prerequisites for the development of skin dysbiosis, which is manifested by a decrease in the diversity of commensal representatives of the resident microbiota and an increase in the growth of pathogens and opportunistic bacteria and fungi. Secondary infection and microbial hypercolonization of the skin in dermatoses (atopic dermatitis, psoriasis and eczema) is the main factor ensuring the chronic course and resistance to traditional methods of therapy. Clinical manifestations of diseases under these conditions acquire features of infection-dependent dermatoses, complicating differential diagnostics and delaying the time of administration of effective therapy. Empirical use of the original drug containing betamethasone dipropionate, gentamicin and clotrimazole is pathogenetically justified in dermatoses of combined genesis and provides rapid relief of manifestations of the inflammatory process. The unique composition and bases of the drug Triderm determine its stable rheological properties, as well as a decrease in the minimum inhibitory concentration of the antibiotic and antimycotic included in its composition to suppress the activity and growth of bacterial-fungal biota in a shorter time compared to analogues.

Keywords: therapy effectiveness, skin microbiome, epidermal barrier, Triderm, eczema, antimicrobial peptides, atopic dermatitis, psoriasis